Viva Financial Statements From 2010 to 2025
| VBIZF Stock | USD 0.25 0.00 0.00% |
Check Viva Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viva Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Viva financial statements analysis is a perfect complement when working with Viva Biotech Valuation or Volatility modules.
Viva |
Viva Biotech Holdings Company Return On Equity Analysis
Viva Biotech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Viva Biotech Return On Equity | 0.031 |
Most of Viva Biotech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viva Biotech Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Viva Biotech Holdings has a Return On Equity of 0.031. This is 100.13% lower than that of the Healthcare sector and 100.09% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 110.0% lower than that of the firm.
Viva Biotech Holdings Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Viva Biotech's current stock value. Our valuation model uses many indicators to compare Viva Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viva Biotech competition to find correlations between indicators driving Viva Biotech's intrinsic value. More Info.Viva Biotech Holdings is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.49 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Viva Biotech Holdings is roughly 2.05 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viva Biotech's earnings, one of the primary drivers of an investment's value.About Viva Biotech Financial Statements
Viva Biotech stakeholders use historical fundamental indicators, such as Viva Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Viva Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Viva Biotech's assets and liabilities are reflected in the revenues and expenses on Viva Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Viva Biotech Holdings. Please read more on our technical analysis and fundamental analysis pages.
Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company was incorporated in 2008 and is headquartered in Shanghai, China. VIVA BIOTECH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2309 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Viva Pink Sheet
Viva Biotech financial ratios help investors to determine whether Viva Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viva with respect to the benefits of owning Viva Biotech security.